Acrux Ltd ARUXF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.04
- Day Range
- $0.03–0.04
- 52-Week Range
- $0.03–0.05
- Bid/Ask
- $0.00 / $0.30
- Market Cap
- $8.86 Mil
- Volume/Avg
- 3,005 / 11,503
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.16
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 36
- Website
- https://www.acrux.com.au
Valuation
Metric
|
ARUXF
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.31 |
Price/Sales | 1.16 |
Price/Cash Flow | — |
Price/Earnings
ARUXF
Financial Strength
Metric
|
ARUXF
|
---|---|
Quick Ratio | 1.94 |
Current Ratio | 2.09 |
Interest Coverage | — |
Quick Ratio
ARUXF
Profitability
Metric
|
ARUXF
|
---|---|
Return on Assets (Normalized) | −1.91% |
Return on Equity (Normalized) | −3.35% |
Return on Invested Capital (Normalized) | −2.53% |
Return on Assets
ARUXF
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dvqylvlr | Bcjr | $570.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mjnpgqdvq | Tfkyf | $107.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ygnkzccq | Zfxjbrh | $105.6 Bil | |
MRNA
| Moderna Inc | Rsmsqfrm | Jmz | $40.8 Bil | |
ARGX
| argenx SE ADR | Bwmpqmxkf | Twgx | $23.7 Bil | |
BNTX
| BioNTech SE ADR | Wqkfhrdny | Zbtk | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jcwvrptjx | Ccwvzv | $19.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wcnqrqqj | Mrfyjk | $16.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fncdqdcv | Hrpgb | $13.6 Bil | |
INCY
| Incyte Corp | Qrwyjgv | Crrbhkg | $12.8 Bil |